LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
ConclusionsThese data highlight the significant impact that AA can have beyond hair loss, especially for patients with severe AA. There was substantial physician –patient alignment on severity assessment. Higher physician-rated AA severity was associated with higher levels of patient-reported disease burden, including anxiety and depression, and work and activity impairment. These data may help inform appropriate treatment strategies. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 1, 2023 Category: Dermatology Source Type: research
CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?
To assess whether the EQ-5D is a sensitive measure of health-related quality of life (HRQoL) in people with alopecia areata (AA) by comparing scores from sub-groups of people defined by the extensiveness of hair loss. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Lloyd, D. Aggio, E. Law, T. Price Source Type: research
EPH203 The Prevalence of Alopecia Areata in Germany: Results of an Insurance Claims Database Analysis
We describe the epidemiology, physician speciality and comorbidities of patients with AA to better understand the disease burden. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Augustin, P.N. Maqhuzu, S. Suess, A.P. Mauer, D. Haeckl, M. Sticherling, T. Pumnea, U. Schwichtenberg Source Type: research
PCR152 Exploring Which Proxy Conditions Are Conceptually Similar to Alopecia Areata, in Terms of Patients Lived Experience and Health-Related Quality of Life: A Scoping Review to Inform HTA Submission
Payers sometimes allow the use of utility values from proxy conditions in cost-effectiveness models, if proven more appropriate. For conditions such as alopecia areata (AA) where generic preference-based measures often fail to capture the full burden of hrQoL to patients, this offers an alternative approach to reimbursement discussions. However, ensuring the correct proxy condition is used is critically important. This scoping review sought to select a suitable proxy condition for AA, by mapping key hrQoL domains and symptoms of importance as defined by patients with lived experience of the condition. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Elgares, A. Biggane Source Type: research
SA28 Evaluation of Disease Epidemiology, Comorbidities, Treatment Patterns, and Healthcare Resource Utilization of Alopecia Areata in United Arab Emirates: A Retrospective Claims Database Study
Alopecia areata (AA) is an autoimmune disorder that impacts approximately 2% of population globally with substantial psychological and economic burden. The current study assessed the disease burden, comorbidities, treatment patterns, and specialties involved in AA diagnosis, with special emphasis on the HCRU of associated comorbidities in patients with AA in Dubai, United Arab Emirates (UAE). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Al Hammadi, M. Farghaly, S. Al Dallal, M.W.A. Zayed, E. Fadwa, C.R. Badarinath, H. Mohamed Source Type: research
Alexithymia prevalence among patients with chronic dermatological diseases in a tertiary hospital, Saudi Arabia
CONCLUSIONS: Alexithymia is prevalent among patients with chronic dermatological diseases and dermatologists' awareness of how to identify and address alexithymia among their patients can play a vital role in improving treatment adherence and outcomes.PMID:38028416 | PMC:PMC10646714 | DOI:10.5114/ada.2023.129944 (Source: Advances in Dermatology and Allergology)
Source: Advances in Dermatology and Allergology - November 29, 2023 Category: Dermatology Authors: Hamad Alfahaad Source Type: research
